Literature DB >> 7890748

A camptothecin-resistant DNA topoisomerase I mutant exhibits altered sensitivities to other DNA topoisomerase poisons.

A M Knab1, J Fertala, M A Bjornsti.   

Abstract

The cytotoxic plant alkaloid camptothecin promotes DNA topoisomerase I-linked nicks in DNA by stabilizing a covalently bound enzyme-DNA complex. In the yeast Saccharomyces cerevisiae, substitution of Arg and Ala for the amino acid residues immediately N-terminal to the active site tyrosine in the yeast and human DNA topoisomerase I mutants, top1 vac, results in camptothecin resistance. To examine the mechanism of drug resistance, we assessed the sensitivity of these enzymes to several classes of DNA topoisomerase poisons. Yeast cells expressing the camptothecin-resistant top1 vac mutants were resistant to all of the camptothecin derivatives cytotoxic to wild-type TOP1-expressing cells. This correlated with a significant reduction in drug-induced DNA cleavage in vitro. However, the yeast and human mutant enzymes differed in their responses to the minor groove binding ligand netropsin and to saintopin, a DNA intercalator that targets both DNA topoisomerase I and II. The yeast mutant enzyme demonstrated enhanced sensitivity to the action of saintopin but was resistant to the inhibitory effects of netropsin. In contrast, the human Top1 vac enzyme was resistant to saintopin and indistinguishable from the wild-type enzyme in its response to the netropsin. These results are discussed in terms of enzyme function and the different modes of action of these DNA topoisomerase poisons.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7890748     DOI: 10.1074/jbc.270.11.6141

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Structure and hydration of the DNA-human topoisomerase I covalent complex.

Authors:  G Chillemi; T Castrignanò; A Desideri
Journal:  Biophys J       Date:  2001-07       Impact factor: 4.033

2.  Role of the linker domain and the 203-214 N-terminal residues in the human topoisomerase I DNA complex dynamics.

Authors:  G Chillemi; M Redinbo; A Bruselles; A Desideri
Journal:  Biophys J       Date:  2004-09-03       Impact factor: 4.033

3.  Topoisomerase assays.

Authors:  John L Nitiss; Eroica Soans; Anna Rogojina; Aman Seth; Margarita Mishina
Journal:  Curr Protoc Pharmacol       Date:  2012-06

4.  Identification of a topoisomerase I mutant, scsA1, as an extragenic suppressor of a mutation in scaA(NBS1), the apparent homolog of human nibrin in Aspergillus nidulans.

Authors:  Marcia R Z Kress Fagundes; Larissa Fernandes; Marcela Savoldi; Steven D Harris; Maria H S Goldman; Gustavo H Goldman
Journal:  Genetics       Date:  2003-07       Impact factor: 4.562

5.  SCT1 mutants suppress the camptothecin sensitivity of yeast cells expressing wild-type DNA topoisomerase I.

Authors:  E A Kauh; M A Bjornsti
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-03       Impact factor: 11.205

6.  Polymer delivery of camptothecin against 9L gliosarcoma: release, distribution, and efficacy.

Authors:  Phillip B Storm; John L Moriarity; Betty Tyler; Peter C Burger; Henry Brem; Jon Weingart
Journal:  J Neurooncol       Date:  2002-02       Impact factor: 4.130

7.  Involvement of the Saccharomyces cerevisiae hydrolase Ldh1p in lipid homeostasis.

Authors:  Mykhaylo O Debelyy; Sven Thoms; Melanie Connerth; Günther Daum; Ralf Erdmann
Journal:  Eukaryot Cell       Date:  2011-04-08

8.  Thr729 in human topoisomerase I modulates anti-cancer drug resistance by altering protein domain communications as suggested by molecular dynamics simulations.

Authors:  Giovanni Chillemi; Ilda D'Annessa; Paola Fiorani; Carmen Losasso; Piero Benedetti; Alessandro Desideri
Journal:  Nucleic Acids Res       Date:  2008-09-02       Impact factor: 16.971

9.  A single mutation in the 729 residue modulates human DNA topoisomerase IB DNA binding and drug resistance.

Authors:  Carmen Losasso; Erica Cretaio; Paola Fiorani; Ilda D'Annessa; Giovanni Chillemi; Piero Benedetti
Journal:  Nucleic Acids Res       Date:  2008-09-04       Impact factor: 16.971

10.  A novel approach for organelle-specific DNA damage targeting reveals different susceptibility of mitochondrial DNA to the anticancer drugs camptothecin and topotecan.

Authors:  M C Díaz de la Loza; R E Wellinger
Journal:  Nucleic Acids Res       Date:  2009-01-16       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.